Literature DB >> 16268877

Perifolliculitis capitis abscedens et suffodiens.

S Ljubojevic1, A Pasic, J Lipozencic, M Skerlev.   

Abstract

Perifolliculitis capitis abscedens et suffodiens (PCAS) is rare chronic, suppurative and inflammatory scalp disease. Its aetiology and pathogenesis is not completely understood. The treatment is usually difficult and often disappointing. We report a case of 29-year-old male who presented with tender, fluctuant nodules and abscesses, with draining pus and patchy alopecia on his scalp for 3 years. A skin biopsy from scalp lesions revealed features that are characteristic of perifolliculitis. Initially, the patient was treated with periodic incision and drainage of the scalp abscesses. The answer was very poor. When admitted to our department, isotretinoin was started at daily dose of 30 mg, because initially his cholesterol and triglyceride levels were mildly increased. When dose was reduced to 10 mg the levels of cholesterol and triglyceride remained normal. A response to treatment was excellent and rapid. The treatment of PCAS represents usually difficulties and frustration for both the patient and the physician. A long course of isotretinoin can be considered as one of the most effective treatment for PCAS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16268877     DOI: 10.1111/j.1468-3083.2005.01215.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  3 in total

1.  Dissecting Cellulitis of the Scalp Responding to Intravenous Tumor Necrosis Factor-alpha Antagonist.

Authors:  Uwe Wollina; Astrid Gemmeke; André Koch
Journal:  J Clin Aesthet Dermatol       Date:  2012-04

Review 2.  Sonography in pathologies of scalp and hair.

Authors:  X Wortsman; J Wortsman; L Matsuoka; T Saavedra; F Mardones; D Saavedra; R Guerrero; Y Corredoira
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

3.  Folliculitis et perifolliculitis capitis abscedens et suffodiens controlled with a combination therapy: systemic antibiosis (metronidazole plus clindamycin), dermatosurgical approach, and high-dose isotretinoin.

Authors:  Georgi Tchernev
Journal:  Indian J Dermatol       Date:  2011-05       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.